Compounding Chemotherapy Market

Category : Healthcare & Life Sciences Reports | Delivery Format : PDF,PPT | Publisher: Reports and Insights | Pages : 322

To learn more about this report, request a free sample copy

Compounding Chemotherapy Market Overview

The report is titled as ‘Compounding Chemotherapy Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the compounding chemotherapy market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. The compounding chemotherapy market is expected to grow at a significant rate in the near future.

The global compounding chemotherapy market was valued US$ 438.9 Mn at the end of 2020 and expected to reach at a value of US$ 761.0 Mn by 2028 with a significant CAGR of 7.1%.

Compounding Chemotherapy Introduction

Compounding can be perceived as the branch of knowledge of amalgamating and making medications and drugs that are specific and unexceptional to the necessities of the patients. These anticancer drugs are developed based on the counsel of the healthcare professional in which the singular elements are combined in conformity with the prescribed dose. The qualified and skilled healthcare workers are allowed to update the prescription for the patient fulfilling their particular needs, including dosage formulations, flavors, deficiency of constituents, and strengths for which the patient is allergic or susceptible.

Compounding Chemotherapy Market Dynamics

The rapid enormous evolution in the healthcare industry in the past couple of decades along with various technological advancements is majorly promoting the idea of compounding chemotherapy in the healthcare sector all around the world, which is ultimately expected to offer major breakthroughs to the growth of the global compounding chemotherapy market in the future years.

By the same token, many pioneering and cutting-edge approaches and strategies have authorized pharmacies to retort to the requirements of medics and propel the growth of the global compounding chemotherapy market in the near future.

Furthermore, the growing lack of opium is also estimated to raise demand worldwide for compounding chemotherapy. Such factors are further anticipated to positively fuel the growth of the global compounding chemotherapy market in the years to come. Other than that, hospitals and other health care professionals are further providing consumers all around the world to obtain benefits from compounded medications, which is ultimately projected to accelerate the growth of the global compounding chemotherapy market in the coming years.

Compounding Chemotherapy Market Segmentation

The global compounding chemotherapy market is segmented on the basis of Dose, Compounding Type, Delivery Method, Sterility, Technology, Compounder Type, Application, and Region. The dose segment of the compounding chemotherapy market is divided into chemotherapeutic and non-chemotherapeutics. On the basis of compounding type, the market is segmented into pharmaceutical ingredient alteration (PIA), currently unavailable pharmaceutical manufacturing (CUPM), and pharmaceutical dosage alteration (PDA). Then, on the basis of delivery method, the market is bifurcated into a gravimetric automated compounding device (weight-based) and volumetric automated compounding device (volume-based). The global compounding chemotherapy market, by sterility, has been segmented into sterile and non-sterile.

The market for the global compounding chemotherapy market, by technology, is bifurcated into with robotic arms and without robotic arms. By compounder type, the market is bifurcated into Pharmoduct, Equashield Pro, Medimix, Integra, and others. Further, the application segment is divided into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, respiratory/lung cancer, and others. By Region, market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Compounding Chemotherapy Market Key Players

The global compounding chemotherapy market is dominated by Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy, Comecer S.P.A., Omnicell, Icon group, Dedalus Group, Arxium, Sterline S.R.L., and Loccioni, among others.

MMC Overview on Compounding Chemotherapy Market Report

The non-identical approach of Reports and Insights stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.

A research report on the compounding chemotherapy market by Reports and Insights is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that support the market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

New product designs and launches

Current product compliance

Reimbursement

Concerns for use of compounding chemotherapy

Advantages of compounding chemotherapy

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to make informed decisions.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s products sales, previous growth rates and market expansion plans are considered to generate market share in the global market.


To learn more about this report, request a free sample copy


1.    Global Compounding Chemotherapy Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Compounding Chemotherapy Market Overview

2.1.    Introduction

2.1.1.    Introduction

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Compounding Chemotherapy Market Snapshot

2.4.    Global Compounding Chemotherapy Market Size And Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast And Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Compounding Chemotherapy Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Porter’s Five Forces Model

2.7.    SWOT Analysis

3.    Compounding Chemotherapy Assessment and Analysis

3.1.    Compounding Chemotherapy Impact Analysis 

3.2.    Actions to encourage use of Compounding Chemotherapy

3.3.    Compounding Chemotherapy Promotional Strategy Recommendation

3.4.    Road Map Analysis

3.5.    GAP Analysis

3.6.    Potential Analysis

4.    Covid-19 Impact on Compounding Chemotherapy Market

4.1.    Impact Analysis of Covid-19 on the global Compounding Chemotherapy market

4.2.    Effect On Value Chain

4.3.    Business Impact W.R.T Revenue 

4.4.    Volatility In Price 

4.5.    Effect On The Overall Trade 

4.6.    Market Impact Analysis In 2020 (Quarter Wise)

5.    Global Compounding Chemotherapy Market, By Dose

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Dose

5.1.2.    BPS Analysis, By Dose

5.2.    Market Revenue (US$Mn) and Forecast, By Dose

5.2.1.    Chemotherapeutic

5.2.2.    Non-chemotherapeutics

5.3.    Global Compounding Chemotherapy Market Attractiveness Index, By Dose

6.    Global Compounding Chemotherapy Market, By Compounding Type

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Compounding Type

6.1.2.    BPS Analysis, By Compounding Type

6.2.    Market Revenue (US$Mn) and Forecast, By Compounding Type

6.2.1.    Pharmaceutical Ingredient Alteration (PIA)

6.2.2.    Currently Unavailable Pharmaceutical Manufacturing (CUPM)

6.2.3.    Pharmaceutical Dosage Alteration

6.3.     Global Compounding Chemotherapy Market Attractiveness Index, By Compounding Type

7.    Global Compounding Chemotherapy Market, By Delivery Method

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Delivery Method

7.1.2.    BPS Analysis, By Delivery Method

7.2.    Market Revenue (US$Mn) and Forecast, By Delivery Method

7.2.1.    Gravimetric Automated Compounding Device (Weight-based)

7.2.2.    Volumetric Automated Compounding Device (Volume-based)

7.3.    Global Compounding Chemotherapy Market Attractiveness Index, By Delivery Method

8.    Global Compounding Chemotherapy Market, By Sterility

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Sterility

8.1.2.    BPS Analysis, By Sterility

8.2.    Market Revenue (US$Mn) and Forecast, By Sterility

8.2.1.    Sterile

8.2.2.    Non-sterile

8.3.    Global Compounding Chemotherapy Market Attractiveness Index, By Sterility

9.    Global Compounding Chemotherapy Market, By Technology

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Technology

9.1.2.    BPS Analysis, By Technology

9.2.    Market Revenue (US$Mn) and Forecast, By Technology

9.2.1.    With Robotic Arms

9.2.2.    Without Robotic Arms

9.3.    Global Compounding Chemotherapy Market Attractiveness Index, By Technology

10.    Global Compounding Chemotherapy Market, By Compounder Type

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Compounder Type

10.1.2.    BPS Analysis, By Compounder Type

10.2.    Market Revenue (US$Mn) and Forecast, By Compounder Type

10.2.1.    Pharmoduct

10.2.2.    Equashield Pro

10.2.3.    Medimix

10.2.4.    Integra

10.2.5.    Others

10.3.    Global Compounding Chemotherapy Market Attractiveness Index, By Compounder Type

11.    Global Compounding Chemotherapy Market, By Application

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Application

11.1.2.    BPS Analysis, By Application

11.2.    Market Revenue (US$Mn) and Forecast, By Application

11.2.1.    Breast Cancer

11.2.2.    Blood Cancer

11.2.3.    Prostate Cancer

11.2.4.    Gastrointestinal Cancer

11.2.5.    Respiratory/Lunch Cancer

11.2.6.    Others

11.3.    Global Compounding Chemotherapy Market Attractiveness Index, By Application

12.    Global Compounding Chemotherapy Market, By Region

12.1.    Introduction

12.1.1.    Annual Growth Rate Comparison, By Region

12.1.2.    BPS Analysis, By Region

12.2.    Market Revenue (US$Mn) and Forecast, By Region

12.2.1.    North America

12.2.2.    Latin America

12.2.3.    Europe

12.2.4.    Asia Pacific

12.2.5.    Middle East 

12.2.6.    Africa

12.3.    Global Compounding Chemotherapy Market Attractiveness Index, By Region

13.    North America Compounding Chemotherapy Market Analysis and Forecast, 2020–2028

13.1.    Introduction

13.1.1.    Annual Growth Rate Comparison, By Country

13.1.2.    BPS Analysis, By Country

13.2.    Market Revenue (US$Mn) and Forecast, By Country

13.2.1.    U.S. Compounding Chemotherapy Market

13.2.2.    Canada Compounding Chemotherapy Market

13.3.    North America Compounding Chemotherapy Market, By Dose

13.3.1.    Chemotherapeutic

13.3.2.    Non-chemotherapeutics

13.4.    North America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounding Type

13.4.1.    Pharmaceutical Ingredient Alteration (PIA)

13.4.2.    Currently Unavailable Pharmaceutical Manufacturing (CUPM)

13.4.3.    Pharmaceutical Dosage Alteration

13.5.    North America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Delivery Method

13.5.1.    Gravimetric Automated Compounding Device (Weight-based)

13.5.2.    Volumetric Automated Compounding Device (Volume-based)

13.6.    North America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Sterility

13.6.1.    Sterile

13.6.2.    Non-sterile

13.7.    North America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Technology

13.7.1.    With Robotic Arms

13.7.2.    Without Robotic Arms

13.8.    North America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounder Type

13.8.1.    Pharmoduct

13.8.2.    Equashield Pro

13.8.3.    Medimix

13.8.4.    Integra

13.8.5.    Others

13.9.    North America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Application

13.9.1.    Breast Cancer

13.9.2.    Blood Cancer

13.9.3.    Prostate Cancer

13.9.4.    Gastrointestinal Cancer

13.9.5.    Respiratory/Lunch Cancer

13.9.6.    Others

13.10.    North America Compounding Chemotherapy Market Attractiveness Index

13.10.1.    By Country

13.10.2.    By Dose

13.10.3.    By Compounding Type

13.10.4.    By Delivery Method

13.10.5.    By Sterility

13.10.6.    By Technology

13.10.7.    By Compounder Type

13.10.8.    By Application

14.    Latin America Compounding Chemotherapy Market Analysis and Forecast, 2020–2028

14.1.    Introduction

14.1.1.    Annual Growth Rate Comparison, By Country

14.1.2.    BPS Analysis, By Country

14.2.    Market (US$Mn) Forecast, By Country

14.2.1.    Brazil Compounding Chemotherapy Market

14.2.2.    Mexico Compounding Chemotherapy Market

14.2.3.    Rest Of Latin America Compounding Chemotherapy Market

14.3.    Latin America Compounding Chemotherapy Market, By Dose

14.3.1.    Chemotherapeutic

14.3.2.    Non-chemotherapeutics

14.4.    Latin America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounding Type

14.4.1.    Pharmaceutical Ingredient Alteration (PIA)

14.4.2.    Currently Unavailable Pharmaceutical Manufacturing (CUPM)

14.4.3.    Pharmaceutical Dosage Alteration

14.5.    Latin America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Delivery Method

14.5.1.    Gravimetric Automated Compounding Device (Weight-based)

14.5.2.    Volumetric Automated Compounding Device (Volume-based)

14.6.    Latin America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Sterility

14.6.1.    Sterile

14.6.2.    Non-sterile

14.7.    Latin America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Technology

14.7.1.    With Robotic Arms

14.7.2.    Without Robotic Arms

14.8.    Latin America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounder Type

14.8.1.    Pharmoduct

14.8.2.    Equashield Pro

14.8.3.    Medimix

14.8.4.    Integra

14.8.5.    Others

14.9.    Latin America Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Application

14.9.1.    Breast Cancer

14.9.2.    Blood Cancer

14.9.3.    Prostate Cancer

14.9.4.    Gastrointestinal Cancer

14.9.5.    Respiratory/Lunch Cancer

14.9.6.    Others

14.10.    Latin America Compounding Chemotherapy Market Attractiveness Index

14.10.1.    By Country

14.10.2.    By Dose

14.10.3.    By Compounding Type

14.10.4.    By Delivery Method

14.10.5.    By Sterility

14.10.6.    By Technology

14.10.7.    By Compounder Type

14.10.8.    By Application

15.    Europe Compounding Chemotherapy Market Analysis and Forecast, 2020–2028

15.1.    Introduction

15.1.1.    Annual Growth Rate Comparison, By Country

15.1.2.    BPS Analysis, By Country

15.2.    Market (US$Mn) Forecast, By Country

15.2.1.    U.K. Compounding Chemotherapy Market

15.2.2.    Germany Compounding Chemotherapy Market

15.2.3.    Italy Compounding Chemotherapy Market

15.2.4.    France Compounding Chemotherapy Market

15.2.5.    Spain Compounding Chemotherapy Market

15.2.6.    Russia Compounding Chemotherapy Market

15.2.7.    Rest Of Europe Compounding Chemotherapy Market

15.3.    Europe Compounding Chemotherapy Market, By Dose

15.3.1.    Chemotherapeutic

15.3.2.    Non-chemotherapeutics

15.4.    Europe Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounding Type

15.4.1.    Pharmaceutical Ingredient Alteration (PIA)

15.4.2.    Currently Unavailable Pharmaceutical Manufacturing (CUPM)

15.4.3.    Pharmaceutical Dosage Alteration

15.5.    Europe Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Delivery Method

15.5.1.    Gravimetric Automated Compounding Device (Weight-based)

15.5.2.    Volumetric Automated Compounding Device (Volume-based)

15.6.    Europe Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Sterility

15.6.1.    Sterile

15.6.2.    Non-sterile

15.7.    Europe Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Technology

15.7.1.    With Robotic Arms

15.7.2.    Without Robotic Arms

15.8.    Europe Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounder Type

15.8.1.    Pharmoduct

15.8.2.    Equashield Pro

15.8.3.    Medimix

15.8.4.    Integra

15.8.5.    Others

15.9.    Europe Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Application

15.9.1.    Breast Cancer

15.9.2.    Blood Cancer

15.9.3.    Prostate Cancer

15.9.4.    Gastrointestinal Cancer

15.9.5.    Respiratory/Lunch Cancer

15.9.6.    Others

15.10.    Europe Compounding Chemotherapy Market Attractiveness Index

15.10.1.    By Country

15.10.2.    By Dose

15.10.3.    By Compounding Type

15.10.4.    By Delivery Method

15.10.5.    By Sterility

15.10.6.    By Technology

15.10.7.    By Compounder Type

15.10.8.    By Application

16.    Asia Pacific Compounding Chemotherapy Market Analysis and Forecast, 2020–2028

16.1.    Introduction

16.1.1.    Annual Growth Rate Comparison, By Country

16.1.2.    BPS Analysis, By Country

16.2.    Market (US$Mn) Forecast, By Country

16.2.1.    China Compounding Chemotherapy Market

16.2.2.    India Compounding Chemotherapy Market

16.2.3.    Japan Compounding Chemotherapy Market

16.2.4.    Australia and New Zealand Compounding Chemotherapy Market

16.2.5.    South Korea Compounding Chemotherapy Market

16.2.6.    Rest of Asia Pacific Compounding Chemotherapy Market

16.3.    Asia Pacific Compounding Chemotherapy Market, By Dose

16.3.1.    Chemotherapeutic

16.3.2.    Non-chemotherapeutics

16.4.    Asia Pacific Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounding Type

16.4.1.    Pharmaceutical Ingredient Alteration (PIA)

16.4.2.    Currently Unavailable Pharmaceutical Manufacturing (CUPM)

16.4.3.    Pharmaceutical Dosage Alteration

16.5.    Asia Pacific Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Delivery Method

16.5.1.    Gravimetric Automated Compounding Device (Weight-based)

16.5.2.    Volumetric Automated Compounding Device (Volume-based)

16.6.    Asia Pacific Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Sterility

16.6.1.    Sterile

16.6.2.    Non-sterile

16.7.    Asia Pacific Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Technology

16.7.1.    With Robotic Arms

16.7.2.    Without Robotic Arms

16.8.    Asia Pacific Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounder Type

16.8.1.    Pharmoduct

16.8.2.    Equashield Pro

16.8.3.    Medimix

16.8.4.    Integra

16.8.5.    Others

16.9.    Asia Pacific Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Application

16.9.1.    Breast Cancer

16.9.2.    Blood Cancer

16.9.3.    Prostate Cancer

16.9.4.    Gastrointestinal Cancer

16.9.5.    Respiratory/Lunch Cancer

16.9.6.    Others

16.10.    Asia Pacific Compounding Chemotherapy Market Attractiveness Index

16.10.1.    By Country

16.10.2.    By Dose

16.10.3.    By Compounding Type

16.10.4.    By Delivery Method

16.10.5.    By Sterility

16.10.6.    By Technology

16.10.7.    By Compounder Type

16.10.8.    By Application

17.    Middle East Compounding Chemotherapy Market Analysis and Forecast, 2020–2028

17.1.    Introduction

17.1.1.    Annual Growth Rate Comparison, By Country

17.1.2.    BPS Analysis, By Country

17.2.    Market (US$Mn) Forecast, By Country

17.2.1.    GCC Countries Compounding Chemotherapy Market

17.2.2.    Israel Compounding Chemotherapy Market

17.2.3.    Rest Of Middle East Compounding Chemotherapy Market

17.3.    Middle East Compounding Chemotherapy Market, By Dose

17.3.1.    Chemotherapeutic

17.3.2.    Non-chemotherapeutics

17.4.    Middle East Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounding Type

17.4.1.    Pharmaceutical Ingredient Alteration (PIA)

17.4.2.    Currently Unavailable Pharmaceutical Manufacturing (CUPM)

17.4.3.    Pharmaceutical Dosage Alteration

17.5.    Middle East Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Delivery Method

17.5.1.    Gravimetric Automated Compounding Device (Weight-based)

17.5.2.    Volumetric Automated Compounding Device (Volume-based)

17.6.    Middle East Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Sterility

17.6.1.    Sterile

17.6.2.    Non-sterile

17.7.    Middle East Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Technology

17.7.1.    With Robotic Arms

17.7.2.    Without Robotic Arms

17.8.    Middle East Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounder Type

17.8.1.    Pharmoduct

17.8.2.    Equashield Pro

17.8.3.    Medimix

17.8.4.    Integra

17.8.5.    Others

17.9.    Middle East Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Application

17.9.1.    Breast Cancer

17.9.2.    Blood Cancer

17.9.3.    Prostate Cancer

17.9.4.    Gastrointestinal Cancer

17.9.5.    Respiratory/Lunch Cancer

17.9.6.    Others

17.10.    Middle East Compounding Chemotherapy Market Attractiveness Index

17.10.1.    By Country

17.10.2.    By Dose

17.10.3.    By Compounding Type

17.10.4.    By Delivery Method

17.10.5.    By Sterility

17.10.6.    By Technology

17.10.7.    By Compounder Type

17.10.8.    By Application

18.    Africa Compounding Chemotherapy Market Analysis and Forecast, 2020–2028

18.1.    Introduction

18.1.1.    Annual Growth Rate Comparison, By Country

18.1.2.    BPS Analysis, By Country

18.2.    Market (US$Mn) Forecast, By Country

18.2.1.    South Africa Countries Compounding Chemotherapy Market

18.2.2.    Egypt Compounding Chemotherapy Market

18.2.3.    North Africa Compounding Chemotherapy Market

18.2.4.    Rest of Africa Compounding Chemotherapy Market

18.3.    Africa Compounding Chemotherapy Market, By Dose

18.3.1.    Chemotherapeutic

18.3.2.    Non-chemotherapeutics

18.4.    Africa Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounding Type

18.4.1.    Pharmaceutical Ingredient Alteration (PIA)

18.4.2.    Currently Unavailable Pharmaceutical Manufacturing (CUPM)

18.4.3.    Pharmaceutical Dosage Alteration

18.5.    Africa Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Delivery Method

18.5.1.    Gravimetric Automated Compounding Device (Weight-based)

18.5.2.    Volumetric Automated Compounding Device (Volume-based)

18.6.    Africa Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Sterility

18.6.1.    Sterile

18.6.2.    Non-sterile

18.7.    Africa Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Technology

18.7.1.    With Robotic Arms

18.7.2.    Without Robotic Arms

18.8.    Africa Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Compounder Type

18.8.1.    Pharmoduct

18.8.2.    Equashield Pro

18.8.3.    Medimix

18.8.4.    Integra

18.8.5.    Others

18.9.    Africa Compounding Chemotherapy Market Revenue (US$Mn) and Forecast, By Application

18.9.1.    Breast Cancer

18.9.2.    Blood Cancer

18.9.3.    Prostate Cancer

18.9.4.    Gastrointestinal Cancer

18.9.5.    Respiratory/Lunch Cancer

18.9.6.    Others

18.10.    Africa Compounding Chemotherapy Market Attractiveness Index

18.10.1.    By Country

18.10.2.    By Dose

18.10.3.    By Compounding Type

18.10.4.    By Delivery Method

18.10.5.    By Sterility

18.10.6.    By Technology

18.10.7.    By Compounder Type

18.10.8.    By Application

19.    Competitive Landscape

19.1.    Company Profiles

19.1.1.    Braun Melsungen AG

19.1.1.1.    Company Overview

19.1.1.2.    Financial Overview

19.1.1.3.    Key Developments

19.1.1.4.    Strategies

19.1.1.5.    Product Analysis

19.1.2.    Pfizer Inc.

19.1.3.    Baxter, Grifols SA

19.1.4.    The Metrix Company

19.1.5.    Added Pharma

19.1.6.    Equashield

19.1.7.    Millers Pharmacy

19.1.8.    Comecer S.P.A.

19.1.9.    Omnicell

19.1.10.    Icon group

19.1.11.    Dedalus Group

19.1.12.    Arxium

19.1.13.    Sterline S.R.L.

19.1.14.    Loccioni

20.    Acronyms

Select License Type

Frequently Asked Questions

The global compounding chemotherapy market was valued US$ 438.9 Mn at the end of 2020 and expected to reach at a value of US$ 761.0 Mn by 2028 with a significant CAGR of 7.1%.

The rapid enormous evolution in the healthcare industry in the past couple of decades and growing lack of opium are the key factors driving the growth of market

The global compounding chemotherapy market is segmented on the basis of Dose, Compounding Type, Delivery Method, Sterility, Technology, Compounder Type, Application, and Region

The global compounding chemotherapy market is dominated by Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy, Comecer S.P.A., Omnicell, Icon group, Dedalus Group, Arxium, Sterline S.R.L., and Loccioni, among others.